The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...

GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.

Gilead Sciences’ twice-yearly injectable pre-exposure prophylaxis (PrEP) drug has been approved by the US Food and Drug ...

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences (Nasdaq: GILD) Yeztugo (lenacapavir) - the company’s ...

Gilead Sciences, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...